Great Novel Therapeutics Biotech & Medicals (ROCO:7427) 3-Year Book Growth Rate : 33.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals 3-Year Book Growth Rate?

Great Novel Therapeutics Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2023 was NT$15.50.

During the past 12 months, Great Novel Therapeutics Biotech & Medicals's average Book Value per Share Growth Rate was 43.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was 33.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 36.90% per year. The lowest was 14.10% per year. And the median was 33.90% per year.

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate falls into.

Great Novel Therapeutics Biotech & Medicals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Great Novel Therapeutics Biotech & Medicals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines